Background {#Sec1}
==========

Homeopathy is a system of medicine based fundamentally on the 'Principle of Similars': a substance capable of causing symptoms of illness in a healthy subject can be used as a medicine to treat similar patterns of symptoms experienced by an individual who is ill; homeopathic medicines are believed to stimulate a self-regulatory healing response in the patient \[[@CR1]\]. There are several distinct forms of homeopathy, the main types being 'individualised homeopathy', 'clinical homeopathy' and 'isopathy'. In *individualised homeopathy*, typically a single homeopathic medicine is selected on the basis of the 'total symptom picture' of a patient, including his/her mental, general and constitutional type. In *clinical homeopathy*, one or more homeopathic medicines are administered for standard clinical situations or conventional diagnoses; where more than one medicine is used in a fixed preparation, it is referred to as a 'combination' (devised by researchers) or 'complex' homeopathic medicine (available as an over-the-counter \[OTC\] proprietary formulation). *Isopathy* is the use of homeopathic dilutions from the causative agent of the disease itself, or from a product of the disease process, to treat the condition \[[@CR1]\]: isopathic medicines include organisms and allergens prescribed on a basis that is different from individualised homeopathic prescribing in the classical sense.

To inform appropriate research development in homeopathy, the nature of its existing research evidence needs to be examined with rigour, objectivity and transparency. In a previous systematic review of randomised controlled trials (RCTs) of *individualised* treatment, we concluded there was a small, statistically significant, effect of the individually prescribed homeopathic medicines that was robust to sensitivity analysis based on reliable evidence; however, the low or uncertain quality of the evidence prevented a decisive conclusion \[[@CR2]\].

In contrast to individualised treatment, placebo-controlled RCTs of *non*-individualised homeopathic treatment evaluate interventions that have involved the same, *standardised*, medication allocated to each and every participant randomised to homeopathy in a given trial: single homeopathic medicine, combination or complex homeopathic medicine, or isopathy. In this RCT context, none of these approaches involves matching a patient with the 'total symptom picture' of an individually prescribed homeopathic medicine: a pre-selected medicine is applied to the *typical* symptoms of a *clinical condition*. In the analysis reported in the present paper, we therefore regard all trials of non-individualised homeopathic treatment as, in effect, testing the same intervention. A study protocol for this systematic review has been published \[[@CR3]\].

Three of five prior comprehensive reviews of homeopathy RCTs, reflecting the broad spectrum of clinical conditions that has been researched, reached the guarded conclusion that the homeopathic intervention probably differs from placebo \[[@CR4]--[@CR6]\]. The fourth such review concluded, 'The results of our meta-analysis are not compatible with the hypothesis that the clinical effects of homeopathy are completely due to placebo' \[[@CR7]\], though the same authors later published supplementary analysis that weakened this conclusion \[[@CR8]\]. The fifth of these global systematic reviews concluded there was "weak evidence for a specific effect of homoeopathic remedies...compatible with the notion that the clinical effects of homoeopathy are placebo effects" \[[@CR9]\]. In their approach, however, each of these 'global' reviews has assessed collectively the findings for individualised *and* non-individualised homeopathy, a method we regard as inappropriate due to the distinction between the two types of intervention in the RCT context. There have been two systematic reviews, with meta-analysis, of *individualised* homeopathy trials: the first was published in 1998 \[[@CR10]\], the most recent in 2014 \[[@CR2]\]. A focused meta-analysis of non-individualised homeopathy RCTs has not previously been reported.

In order to synthesise the findings from placebo-controlled RCTs of non-individualised homeopathy we conducted an up-to-date systematic review and meta-analysis, testing the following null hypothesis: across the entire range of clinical conditions that have been researched, the main outcome of treatment using a non-individualised homeopathic medicine cannot be distinguished from that using placebo. An additional aim, further informing future research, was to quantify any effect of non-individualised homeopathic treatment for each clinical condition for which there is more than a single eligible RCT.

Methods {#Sec2}
=======

Methods comply fully with the *PRISMA* 2009 Checklist (Additional file [1](#MOESM1){ref-type="media"}) and with our published protocol \[[@CR3]\], which does not have a *PROSPERO* registration number.

Search strategy, data sources and trial eligibility {#Sec3}
---------------------------------------------------

We conducted a systematic literature search to identify RCTs that compared non-individualised homeopathy with a placebo, for any clinical condition \[[@CR11]\]. Each of the following electronic databases was searched from its inception up to the end of 2011, with updated searches of the same databases up to the end of 2014: AMED; CAM-Quest®; CINAHL; Cochrane Central Register of Controlled Trials; Embase; Hom-Inform; LILACS; PubMed; Science Citation Index and Scopus. For the update, CORE-Hom® was also searched, using the term 'randomised' or 'unknown' in the *Sequence Generation* field.

The full electronic search strategy for PubMed (Cochrane Highly Sensitive Search Strategy) is given in our previous paper \[[@CR11]\]: "((homeopath\* *or* homoeopath\*) *and* ((randomized controlled trial \[pt\]) *or* (controlled clinical trial \[pt\]) *or* (randomized \[tiab\]) *or* (placebo \[tiab\]) *or* (clinical trials as topic \[mesh:noexp\]) *or* (randomly \[tiab\]) *or* (trial \[ti\]))) *not* (animals \[mh\] *not* humans \[mh\])".

As stated in our published protocol \[[@CR3]\], we then excluded trials: of crossover design; of radionically prepared homeopathic medicines; of homeopathic prophylaxis; of homeopathy combined with other (complementary or conventional) intervention; for other specified reasons. The final explicit exclusion criterion was that there was obviously no blinding of participants and practitioners to the assigned intervention; for example, a trial described by the original authors as 'single \[i.e. patient-\] blinded' was automatically excluded. All remaining trials were eligible for systematic review.

Outcome definitions {#Sec4}
-------------------

For each trial, and for the purposes of risk-of-bias assessment and meta-analysis, we identified a single 'main outcome measure' using a refinement of the approaches adopted by Linde et al. \[[@CR7]\] and by Shang et al. \[[@CR9]\]. Each trial's 'main outcome measure' was identified based on the following hierarchical ranking order (consistent with the WHO International Classification of Functioning (ICF) linked to health condition \[[@CR12]\]):MortalityMorbidity○ Treatment failure○ Pathology; symptoms of diseaseHealth impairment (loss/abnormality of function, incl. presence of pain)Limitation of activity (disability, incl. days off work/school because of ill health)Restriction of participation (quality of life)Surrogate outcome (e.g. blood test data, bone mineral density).

We followed the WHO ICF system regardless of what measure may have been identified by the investigators as their 'primary outcome'. In cases where, in the judgment of the reviewers, there were two or more outcome measures of equal greatest importance within the WHO ICF rank order, the designated 'main outcome measure' was selected randomly from those two or more options using the toss of coins or dice.

Unless otherwise indicated, the single end-point (measured from the start of the intervention) associated with the designated 'main outcome measure' was taken as the last follow-up at which data were reported for that outcome.

Data extraction {#Sec5}
---------------

Two reviewers (RTM and either JC, JRTD, LL, SM, NR or C-MM) identified the main outcome measure and then independently extracted data for each trial using a standard recording approach \[[@CR3]\]. The data extracted per trial included, as appropriate: demographics of participants (gender, age range, medical condition); study setting; potency or potencies of homeopathic medicines; whether a pilot trial; 'main outcome measure' (see above) and measured end-point; funding source/s. The statistical items noted were whether statistical power calculation carried out; whether intention-to-treat (ITT) analysis; sample size and missing data for each intervention group. Discrepancies in the interpretation of data were discussed and resolved by consensus.

Assessment of risk of bias {#Sec6}
--------------------------

We used the domains of assessment as per the Cochrane risk-of-bias appraisal tool \[[@CR13]\]. The extracted information enabled appraisal of freedom from risk of bias per domain: 'Yes' (low risk), 'Unclear' risk or 'No' (high risk). We applied this approach to each of the seven domains: sequence generation (domain I); allocation concealment used to implement the random sequence (II); blinding of participants and study personnel (IIIa); blinding of outcome assessors (IIIb); incomplete outcome data (IV); selective outcome reporting (V); other sources of bias (VI). The source of any research sponsorship (i.e. potential for vested interest) was taken into account for sub-group analysis (see below), but not in risk-of-bias assessment per se.

Reflecting appropriately the designated main outcome measure, we rated risk of bias for each trial across all seven domains and using the following classification \[[@CR3]\]:Rating A = *Low risk of bias* in all seven domains.Rating B*x* = *Uncertain risk of bias* in *x* domains; low risk of bias in all other domains.Rating C*y.x* = *High risk of bias* in *y* domains; uncertain risk of bias in *x* domains; low risk of bias in all other domains.

### Designating an RCT as 'reliable evidence' {#Sec7}

An 'A'-rated trial was designated *reliable evidence*. We also designated a 'B1'-rated trial *reliable evidence* if the uncertainty in its risk of bias was for one of domains IV, V or VI only (i.e. it was required to be judged free of bias for each of domains I, II, IIIA and IIIB) \[[@CR3]\]; in tabulations and text below, this rating is shown as 'B1\* (*minimal risk of bias*)'.

Study selection for meta-analysis {#Sec8}
---------------------------------

All RCTs that were included in the systematic review were potentially eligible for meta-analysis. If the original RCT paper did not provide adequate information on our selected main outcome measure to enable calculation of the SMD or the OR, we excluded the trial from the meta-analysis, and described the outcome as 'not estimable'; consistent with Cochrane assessment criteria \[[@CR13]\], such a trial was thus attributed *high risk of bias* in domain V.

Statistical analysis {#Sec9}
--------------------

### Data preparation {#Sec10}

For a continuous main outcome measure, the mean, standard deviation (SD) and number of subjects were extracted for homeopathy and placebo groups and the unbiased standardised mean difference (SMD) calculated, so that a negative SMD reflected a difference in favour of homeopathy. We did not adjust values to compensate for any inter-group differences at baseline. For a dichotomous main outcome measure, the number of subjects with a favourable outcome and the total number of subjects in each group were extracted to enable calculation of the odds ratio (OR), with values greater than 1 reflecting a difference in favour of homeopathy.

For a given trial comprising more than two study groups, only the data concerning comparisons between non-individualised homeopathy and placebo were extracted from the paper. For a trial in which there were two or more homeopathy groups, those groups' data were combined in analysis where relevant and feasible: for a dichotomous measure, combining data merely required summing the events and sample sizes; for a continuous measure, combining data was feasible only where SD was derivable[1](#Fn1){ref-type="fn"}.

For the pooled meta-analysis, a single measure of effect size was required to enable pooling of all relevant trials: ORs were transformed to SMD using a recognised approximation method \[[@CR14]\]. This is a deviation from the protocol, which stated that SMD would be transformed to OR, as in a previous paper \[[@CR2]\]. SMD and OR are equally valid statistics. The reasoning behind using SMD instead of OR is that the latter is intuitively associated with a dichotomous outcome, whereas the former has a direct connection with 'effect size' and indicates that, for the meta-analysis, it has been derived via transformation from other measures (including OR). Whichever of these two metrics is used, their results are interchangeable and their interpretation is identical. 'Effect size' was interpreted as follows: SMD \<0.40 = 'small'; SMD 0.40 to 0.70 = 'moderate'; SMD \>0.70 = 'large' \[[@CR14]\]. Via the SMD-to-OR transformation factor above \[[@CR14]\], these values correspond, respectively, to: OR \<2.10 = 'small'; OR 2.10 to 3.60 = 'moderate'; OR \>3.60 = 'large', which we used for our previous paper \[[@CR2]\].

### Heterogeneity and publication bias {#Sec11}

Due to the known clinical heterogeneity between studies, random-effects meta-analysis regression models \[[@CR15]\] were used to derive pooled estimators and for sub-group / moderator analyses. Estimates were derived along with their 95% confidence intervals (CI) and *p* values. The *I* ^2^ statistic was used to assess the variability between studies: it gives the percentage of the total variability in the estimated effect size (which is composed of between-study heterogeneity plus sampling variability) that is attributable to heterogeneity. The *I* ^2^ statistic can take values between 0 and 100%: *I* ^2^ = 0% means that all of the heterogeneity is due to sampling error, and *I* ^2^ = 100% means that all variability is due to true heterogeneity between studies.

Funnel plots and Egger's test of asymmetry \[[@CR16], [@CR17]\] and the 'trim-and-fill' method \[[@CR18], [@CR19]\] were used to assess the impact of publication bias.

All statistical analyses were carried out in *R* version 3.1.2 and using the *meta* package \[[@CR20]\].

Sensitivity analysis {#Sec12}
--------------------

The sensitivity analysis aimed to ascertain the impact of trials' risk-of-bias rating on the pooled SMD: we examined the effect of cumulatively removing data from the meta-analysis by each trials' rating, beginning with the lowest ranked 'C'-rated trial/s.

Sub-group analysis {#Sec13}
------------------

Included in sub-group analysis was whether a trial: (a) had been included or not in previous meta-analysis \[[@CR9]\]; (b) was a 'pilot' study; (c) necessitated our use of imputed data for the meta-analysis; (d) was free of vested interest; (e) investigated either an 'acute' or a 'chronic' clinical condition.

As was implicit in the study protocol \[[@CR3]\], and as presented in a previous paper \[[@CR2]\], we also included the following in sub-group analysis: (f) whether a trial had sample size that was greater or less than the median for those included in meta-analysis; (g) whether a trial used homeopathic medicine/s with potency ≥12C or \<12C (12-times serial dilution of 1:100 starting solution), a concentration sometimes regarded as equivalent to the 'Avogadro limit' for molecular dose \[[@CR21]\]; potency was defined as 'mixed' if a combination medicine in a given trial comprised a mixture of ≥12C and \<12C potencies.

As recognised by Cochrane, some issues suitable for such analysis are identified during the review process itself \[[@CR22]\]. Thus, we additionally carried out sub-group analysis depending on whether (h) a trial had investigated a combination, an OTC complex, an isopathic or a single remedy.

### Disease-specific treatment effect of non-individualised homeopathy {#Sec14}

Analysis was carried out by clinical condition, in cases where there were ≥2 RCTs with extractable main outcome. Analysis was additionally carried out by *category* of clinical condition, including each category for which there were data from ≥2 RCTs. RCT nomenclature for clinical conditions and their categories was previously characterised \[[@CR11]\][2](#Fn2){ref-type="fn"}.

All sub-group analyses were conducted before and after removal of 'C'-rated trials \[[@CR2]\].

Results {#Sec15}
=======

Included studies {#Sec16}
----------------

The *PRISMA* flowchart from the original comprehensive literature search (up to and including 2011) was published previously \[[@CR11]\]. An updated *PRISMA* flowchart is given in Fig. [1](#Fig1){ref-type="fig"}, identifying a total of 553 records.[3](#Fn3){ref-type="fn"} Four-hundred and fifty-four remained after removal of duplicates. After excluding 95 due to type of record (book chapter, thesis, abstract and other minor article), Three-hundred and fifty-nine full-text records were then assessed for eligibility. Two-hundred and eighty-seven were excluded for the general reasons summarised in Fig. [1](#Fig1){ref-type="fig"}; 38 of these same 287 were excluded from the present systematic review for the additionally specified reasons shown in Additional file [2](#MOESM2){ref-type="media"}.[4](#Fn4){ref-type="fn"} The finally remaining 72 records (75 RCTs) were thus included in this systematic review; data were not extractable from 21 of those, leaving 51 records (54 RCTs) available for meta-analysis---see Additional file [2](#MOESM2){ref-type="media"} for details of the 21 records excluded from meta-analysis.Fig. 1Updated *PRISMA* flowchart for all records published up to and including 2014

Characteristics of included studies {#Sec17}
-----------------------------------

The 75 RCTs represent 48 different clinical conditions across 15 categories (Table [1](#Tab1){ref-type="table"}). Each of 52 RCTs studied a condition that was acute in nature; each of 23 studied a chronic condition. Homeopathic potency was ≥12C in 29 trials, and not exclusively ≥12C for 7 trials (mix of \>12C and \<12C for 6 trials; unstated for 1 trial); potency was \<12C in 39 trials. Seventeen trials were free of vested interest; 24 trials were *not* free of vested interest; 34 trials did not enable certainty in this assessment.Table 1Demographic data for 75 randomised controlled trials (RCTs) of non-individualised homeopathy: 21 excluded from meta-analysis shown by italics at first author\'s name\#First authorYearCategoryConditionAcute/ ChronicParticipants' demographicsStudy settingPotency ≥12CHom. typeFunding sourceFree of vested interest ^a^A42*Aabel*2001Allergy and AsthmaSeasonal allergic rhinitisAcutePatients treated for hay fever due to birch pollen allergySpecialist outpatient department in NorwayYIsopathyResearch Council of Norway. Homeopathic remedy and placebo tablets were gift from DCG, Gothenburg, SwedenNA43*Aabel*2000Allergy and AsthmaSeasonal allergic rhinitisAcutePatients treated for hay fever due to birch pollen allergySpecialist outpatient department in NorwayYIsopathyResearch Council of Norway. Homeopathic remedy and placebo tablets were gift from DCG, Gothenburg, SwedenNA44*Aabel*2000Allergy and AsthmaSeasonal allergic rhinitisAcutePatients treated for hay fever due to birch pollen allergySpecialist outpatient department in NorwayYIsopathyResearch Council of Norway. Homeopathic remedy and placebo tablets were gift from DCG, Gothenburg, SwedenNA47Baker2003Mental DisorderAnxietyAcuteAnxious students, aged 18-60 yearsUniversity, AustraliaNSingle'Brauer Biotherapies Pty Ltd (Adelaide) manufactured the homeopathic preparation specifically for the study'UA48Balzarini2000DermatologyRadiodermatitisAcutePatients with dermatitis caused by radiotherapy for breast cancerRehabilitation and palliative care department, ItalyMixedCombn.None statedUA49Beer1999Obstetrics and GynaecologyInduction of labourAcuteWomen (at least 18 years old) between 38 and 42 weeks' gestation and cervical dilation (≤3 cm)Akademisches Lehrkrankenhaus der RWTH AachenNSingleNone statedUA50Belon2006ToxicologyArsenic toxicityChronicPeople at high risk of arsenic contaminationRural village, IndiaYSingleHom pharmNA51*Belon*2007ToxicologyArsenic toxicityChronicPeople at high risk of arsenic contaminationRural village, IndiaYSingleHom pharmNA52Bergmann (a)2000Obstetrics and GynaecologyFemale infertility: oligomenorrhoeaChronicWomen, age 18 - 40Universitäts-Frauenklinik HeidelbergNOTC complexNone statedUA52Bergmann (b)2000Obstetrics and GynaecologyFemale infertility: amenorrhoeaChronicWomen, age 18 - 40Universitäts-Frauenklinik HeidelbergNOTC complexNone statedUA53*Bernstein*2006DermatologyPsoriasisAcutePatients with psoriasisDermatology Centre in the USANSingle"Supported in part" by Apollo Pharmaceuticals Inc., manufacturers of ReliévaNA55*Berrebi*2001Obstetrics and GynaecologyPostpartum lactationAcuteWomen immediately after childbirth and who did not wish to breast-feedChildbirth unit, university hospital, Toulouse, FranceNCombn.Hom pharmNA56Bignamini1987CardiovascularHypertensionChronicElderly males or females with hypertensionTwo old people's homes, ItalyYSingle"We thank Laboratoires Boiron for material provided"UA59Cialdella2001Mental DisorderWithdrawal of benzodiazepinesChronicMen and women aged \>18 years, taking BZD for \>3 mo.GP practices in France (multi-centre)NOTC complex ^b^External (hom pharm / govt.)NA60Clark2000MusculoskeletalPlantar fasciitisAcutePatients treated with heel pain due to fasciitisPodiatry clinic, EnglandYSingleNone statedUA272Colau2012Obstetrics and GynaecologyMenopausal syndromeChronicWomen aged ≥50 years; experienced amenorrhea for \>12 months; spontaneously complained of hot flashes that had started \<2 years previously35 gynaecologist private practices in FranceNOTC complexHom pharm.NA61Cornu2010Surgery and AnaesthesiologyPost-operative bleedingAcuteMales or females, \>18 years old, for whom elective aortic valve surgery plannedUniversity hospital department, FranceNCombn.Financially supported and assisted in design by Laboratoires Boiron, but 'conducted in total independence'UA62Diefenbach1997Respiratory InfectionBronchitisAcutePatients (M/F) with bronchitis4 doctors' practices in GermanyNOTC complexNone statedUA63Ernst1990CardiovascularVaricose veinsAcuteVaricose veins in the legsRehabilitation clinic in AustriaNOTC complexNone statedUA64Ferley1989Respiratory InfectionInfluenzaAcuteAge ≥12 years, flu-like symptoms, temp ≥38CGeneral practices in Rhône-Alpes region, FranceY^a^IsopathyNone statedUA67Frass2005Respiratory InfectionTracheal secretionsAcutePatients with accumulation of heavy secretions in the tracheaIntensive Care Unit at a university hospital in AustriaYSingleNone statedUA68Freitas1995Allergy and AsthmaChildhood asthmaChronicChildren aged 12 mo to 12 years, with a mild to severe asthma crisis in the previous 6 mo.Outpatient clinic in São Paulo, BrazilNSingleNone statedUA69*Friese*2007Ear, Nose and ThroatSinusitisAcutePatients from 18 - 65 (m/f)10 medical centres in UkraineNOTC complexNone statedUA70Friese1997Ear, Nose and ThroatAdenoidAcuteChildren (M/F) between age 4 and 10Universitäts Kinderklinik TübingenMixedCombn.Remedies were gift from hom pharm.NA74Gerhard (a)1998Obstetrics and GynaecologyFemale infertility: amenorrhoeaChronicWomen with secondary amenorrhoeaUniversity hospital, GermanyNOTC complexDirect support from the company that provided the homeopathic medicine for the trial (senior author is company employee)NA74Gerhard (b)1998Obstetrics and GynaecologyFemale infertility: luteal insufficiencyChronicWomen with luteal insufficiencyUniversity hospital, GermanyNOTC complexDirect support from the company that provided the homeopathic medicine for the trial (senior author is company employee)NA74Gerhard (c)1998Obstetrics and GynaecologyFemale infertility: idiopathicChronicWomen with idiopathic infertilityUniversity hospital, GermanyNOTC complexDirect support from the company that provided the homeopathic medicine for the trial (senior author is company employee)NA75GRECHO1989Surgery and AnaesthesiologyPost-operative ileusAcuteMen and women aged \>18 years, having one of several stated operations12 hospitals in FranceMixedCombn.Govt.YA274*Harrison*2013Mental DisorderInsomniaChronicMales aged 18-40, with chronic primary insomnia: at least 3 days per week for period of 1 mo to 10 yearsUniversity clinicNCombn.UniversityYA76*Hart*1997Surgery and AnaesthesiologyPost-operative painAcutePatients with abdominal hysterectomyHospital, EnglandYSingleNone statedUA78*Hitzenberger*2005CardiovascularHypertensionChronicHypertensive patients (M/F)Not explicitly mentionedNOTC complexThe study was funded, but it is not stated by whomUA79Hofmeyr1990Obstetrics and GynaecologyPostpartum painAcutePostpartum women with episiotomy or perineal tearing requiring sutureUniversity hospital, South AfricaNSingle ^b^None statedUA80*Jacobs*2006GastroenterologyChildhood diarrhoeaAcuteChildren with a history of acute diarrhoeaTwo municipal clinics, HondurasYCombn.External (hom research foundation)YA81Jacobs2007Tropical DiseaseDengue fever symptomsAcutePatients over age 12 with a case definition of dengueTwo health centres, HondurasYCombn.External (hom research foundation); meds 'furnished' by hom pharmUA83Kaziro1984Surgery and AnaesthesiologyPost-operative pain/swellingAcutePatients with extraction of impacted wisdom teethDental hospital, EnglandYSingleNone statedUA84Khuda-Bukhsh2005ToxicologyArsenic toxicityChronicPeople at high risk of arsenic contaminationRural village, IndiaYSingleHom pharm.NA85Khuda-Bukhsh2011ToxicologyArsenic toxicityChronicPeople at high risk of arsenic contaminationRural village, IndiaYSingleHom pharm.NA86Kim2005Allergy and AsthmaSeasonal allergic rhinitisAcuteAsthmatic people allergic to house dust miteCollege of Naturopathic Medicine and Health Sciences, USANIsopathyInternal / External (hom pharm)NA88*Kolia-Adam*2008Mental DisorderInsomniaChronicMales or females, 18-50 years, suffering from insomnia for \> 1 yearUniversity health clinic, South AfricaYSingleNone statedUA89Kotlus2010Surgery and AnaesthesiologyPost-operative bruisingAcuteMales undergoing upper blepharoplastyUniversity department of ophthalmology, USAYCombn.Supported in part by external foundationYA91*Labrecque*1992DermatologyWartsChronicAged 6-59 years and at least 1 plantar wart untreated during previous 3 monthsHospital-based family medicine unit, CanadaMixedCombn.Hospital pharmacyYA92Leaman1989DermatologyMinor burnsAcuteAged 15-60 years with minor burns within previous 6 hHospital Accident and Emergency Dept, EnglandYSingleNone statedUA93Lewith2002Allergy and AsthmaAllergic asthmaChronicAsthmatic people allergic to house dust miteHospital clinic, EnglandYIsopathyInternal / External (charity) / Purchase from hom pharmYA94Lipman1999MiscellaneousSnoringAcutePeople treated for snoringENT specialist clinic in the USANOTC complexNone statedUA293Malapane2014Ear, Nose and ThroatTonsillitisAcuteChildren, aged 6-12 years, with acute viral tonsillitisUniversity department of homeopathy, South AfricaNOTC complexNone statedUA95*McCutcheon*1996Mental DisorderAnxietyAcuteAdults with above average anxietyUniversity, USANOTC complexHom pharmNA275Naidoo2013Allergy and AsthmaAllergic skin reactionAcuteMales or females, aged 18 to 45; positive skin test; living with a cat for a period of ≥ 6 mo; suffering from allergy-like symptomsUniversity health training centreNCombn.None statedUA100Oberbaum2001Oral/DentalStomatitisAcuteCancer patients with stomatitisChildren's Medical Centre in IsraelNOTC complexNone statedUA101Oberbaum2005Obstetrics and GynaecologyPostpartum bleedingAcuteWomen after childbirthMedical centre in IsraelMixedCombn.Research foundationYA103Padilha2011ToxicologyLead poisoningAcuteWorkers at risk of lead contaminationClinic of battery plant, BrazilYSingleExplicitly no funding sourceYA104Papp1998Respiratory InfectionInfluenzaAcuteAge 12-60 years, specified flu-like symptoms, onset within last 24 h, temp ≥38CGeneral or specialist medical practices, GermanyY^a^ IsopathyNone statedUA105Paris2008Surgery and AnaesthesiologyPost-operative analgesic intakeAcuteMale or female, aged 18-60 years, undergoing surgery of anterior cruciate ligamenUniversity hospital, FranceNCombn.Hom pharmNA108Rahlfs1976GastroenterologyIrritable bowel syndromeAcutePatients, male or female, aged 20-60, with diagnosis of irritable bowel syndrome12 general medical practices in GermanyNSingle ^b^None statedUA109Rahlfs1978GastroenterologyIrritable bowel syndromeAcutePatients, male or female, aged 20-60, with diagnosis of irritable bowel syndrome39 general medical practices in GermanyNSingleExternal (hom research foundation)YA277*Razlog*2012Mental DisorderADHDChronicSchool children, aged 5-11, diagnosed with ADHDPrimary schools in South AfricaNSingleUniversityYA111Reilly1986Allergy and AsthmaSeasonal allergic rhinitisAcutePatients aged over 5 with at least a 2-year history of seasonal rhinitis and current symptoms of grass pollen allergyTwo hospital clinics and 26 NHS general practitioners in the UKYIsopathyExternal: charity; govt.YA112Reilly1994Allergy and AsthmaAllergic asthmaChronicPatients aged over 16 with at least a 1-year history of asthma and reactive to inhaled allergensAsthma outpatient clinic, ScotlandYIsopathyExternal / purchase from hom pharmYA113Robertson2007Surgery and AnaesthesiologyPost-operative painAcutePatients over the age of 18 undergoing tonsillectomyHospital, EnglandYSingleInternal / External (hom pharm)NA116*Schmidt*2002MiscellaneousThose benefited by reduced body weightAcuteFasting patients encountering static or increased body weightHospital for internal and complementary medicine, GermanyYSingle"The foundation of the Krankenhaus für Naturheilweisen funded the study, paying salaries or fees to contributors and collaborators."UA117*Seeley*2006Surgery and AnaesthesiologyPost-operative bruisingAcuteFemale patients undergoing elective rhytidectomyHospital, CanadaUnknownSingleHom pharm.NA278*Sencer*2012Oral/DentalMucositisAcutePatients aged 3-25 years, undergoing myeloablative haematopoietic SCT for malignant and non-malignant conditionsOncology centres in USA, Canada and IsraelNOTC complexGovernment (NIH) grantYA120Singer2010Surgery and AnaesthesiologyPost-operative painAcutePatients (M/F) age \> = 182 centresNOTC complexFinancial support by producing company which 'supplied the study medication' but, by contractual agreement, had 'no control over the flow of the study, the data analysis, or the decision when and where to publish the study findings'YA122*Stevinson*2003Surgery and AnaesthesiologyPost-operative pain/swellingAcuteAged 18--70 years undergoing elective hand surgery for carpal tunnel syndromeHospital, EnglandY / NSingle ^b^Hom. research foundation / drugs 'supplied by' hom pharmUA123Taylor2000Allergy and AsthmaPerennial allergic rhinitisChronicPatients with allergy to house dust mites, animals, pollens or foodsSpecialist outpatient department in the UKYIsopathyExternal (hom and non-hom charities)YA125Tveiten1991MusculoskeletalMuscle sorenessAcuteMale marathon runners, NorwayCity of OsloYSingleNone statedUA126Tveiten1998MusculoskeletalMuscle sorenessAcuteMarathon runners, NorwayCity of OsloYSingleResearch Council of Norway. Homeopathic remedy and placebo tablets were gift from hom pharm.NA128Vickers1998MusculoskeletalMuscle sorenessAcuteLong-distance runners, aged 18 or over, EnglandLondon communityYSingleCharity / drugs gifted by hom pharmNA130*Weiser*1994Ear, Nose and ThroatSinusitisChronicPatients (M/F) with chronic sinusitis11 ENT doctors' practices in GermanyNOTC complex ^b^None statedUA131Wiesenauer1985Allergy and AsthmaSeasonal allergic rhinitisAcutePatients treated for hay feverDoctors' practices in GermanyNSingleExternal (hom pharm)NA132*Wiesenauer*1989Ear, Nose and ThroatSinusitisAcutePatients (M/F) with acute or chronic sinusitis47 doctors' practicesNCombn. ^c^Funded by two foundationsYA133Wiesenauer1990Allergy and AsthmaSeasonal allergic rhinitisAcuteM/F, all ages54 doctors' practicesNSingleFunded by two foundationsYA134Wiesenauer1991RheumatologyRheumatoid arthritisChronicPatients (m/f), age 18 - 70, with chronic polyarthritis6 doctors' practicesNOTC complexNone statedUA135Wiesenauer1995Allergy and AsthmaSeasonal allergic rhinitisAcutePatients treated for hay feverDoctors' practices in GermanyNSingleNone statedUA136Wolf2003Surgery and AnaesthesiologyPost-operative painAcuteAge 10 - 65 (M/F), varicose veinsGefäßchirurgische Klinik in Berlin-BuchNSingleRemedies were gift from hom pharm.NA137Zabolotnyi2007Ear, Nose and ThroatSinusitisAcutePatients, aged 18-60 years, treated for acute maxillary sinusitis, with at least 8 d of symptomsENT specialist clinics, UkraineNOTC complexNone statedU*Y* yes, *U* unclear, *N* no, *Combn.* combination, *M/F* male/female^a^Vested interest: support (direct, through research sponsorship; indirect, via gifted medicines) from company that provided homeopathic medicines for the trial^b^Single RCT comprising two homeopathy groups^c^Single RCT comprising three homeopathy groups

Summary of findings {#Sec18}
-------------------

For each trial, Table [2](#Tab2){ref-type="table"} includes details of the sample size, the identified main outcome measure (and whether dichotomous or continuous) and the study end-point. Seventeen trials were described in the original paper as a 'pilot' (or 'preliminary' or 'feasibility') study. A power calculation was carried out for 28 of the trials. ITT was the basis for analysis in 21 trials. Mean attrition rate was 14.6%. The main outcome variable was dichotomous in 25 studies and continuous in the other 50. The total sample size for the 54 meta-analysable trials was *5032*; the median sample size was 62.5 (inter-quartile range, 36 to 107). Meta-analysable studies included 45 different main outcome measures and for an end-point that ranged from 6 h to 6 months. Table [2](#Tab2){ref-type="table"} also indicates the 25 analysed trials in our study that we have in common with those included in the meta-analysis data reported by Shang et al. \[[@CR9]\].Table 2Summary of findings table: 21 excluded from meta-analysis shown by italics at first author\'s name\#First authorYearPilotPower calc.ITT samplePP samplePP sample \> median (62.5)Attrition rate %Original ITT analysis'Main' outcome identifiedNature of 'main' outcomeEnd-pointA42*Aabel*2001NN5151N0.0NDaily symptom score (VAS)Continuous10 daysA43*Aabel*2000NY7066Y5.7NDaily symptom scoreContinuous32 daysA44*Aabel*2000NY8073Y8.8NDaily symptom score (VAS)Continuous10 daysA47Baker2003NY?44N?NRevised Test Anxiety (RTA) scaleContinuous4 daysA48^b^Balzarini2000NN6661N7.6NIndex of Total Severity during Recovery (re: skin colour, temp, oedema, pigmentation)Continuous7--8 weeksA49^b^Beer1999NN4040N0.0YTime between to regular uterine contractionsContinuous7 h or induction of labourA50Belon2006NN4343N0.0NReversal in expression of antinuclear antibody titreDichotomous1 monthA51*Belon*2007YN3925N35.9NBlood arsenic concentrationContinuous2 monthsA52^b^Bergmann (a)2000NY?37N?NCycle normalisationDichotomous3 months or 3 cyclesA52^b^Bergmann (b)2000NY?30N?YCycle normalisationDichotomous3 months or 3 cyclesA53*Bernstein*2006NN200171Y14.5NPsoriasis Area Severity IndexContinuous12 weeksA55*Berrebi*2001NN7171Y0.0NMammary pain (VAS)Continuous4 daysA56Bignamini1987NN3432N5.9N(Systolic) Blood pressureContinuous4 weeksA59^b^Cialdella2001NY9661N36.5Y"Success rate" for clinical global impressionDichotomous30 daysA60Clark2000YN1814N22.2NDaily pain (100 mm VAS)Continuous14 daysA272Colau2012NY108101Y6.5YHot flash scoreContinuous12 weeksA61Cornu2010YY9292Y0.0YCumulated blood loss at drain removalContinuousUp to 7 dA62^b^Diefenbach1997NN258209Y19.0YTreatment success ('very good' + 'good' results) -- physician-assessedDichotomousUp to 3 weeksA63^b^Ernst1990NN122 ^a^122 ^a^N0.0NVenous filling timeContinuous24 daysA64^b^Ferley1989NN478462Y3.3NProportion of patients recovered (from 5 cardinal symptoms and from temp \> 37.5)DichotomousBy 48 hA67Frass2005NN5550N9.1NTotal volume of tracheal secretions per dayContinuous2 daysA68^b^Freitas1995NN8669Y19.8NScore of intensity, frequency and duration of symptomsContinuous6 monthsA69*Friese*2007NN14468Y52.8YSinusitis symptoms scoreContinuous21 daysA70^b^Friese1997NY9782Y15.5NFrequency of non-adenoidectomy (imputed)Dichotomous3 monthsA74Gerhard (a)1998NY3828N26.3NFrequency of pregnancyDichotomous3 monthsA74Gerhard (b)1998NY2721N22.2NFrequency of pregnancyDichotomous3 monthsA74Gerhard (c)1998NY3117N45.2NFrequency of pregnancyDichotomous3 monthsA75GRECHO1989NY300300Y0.0NNumber of hours from operation until first stoolContinuousUp to c.100 hA274*Harrison*2013YN3428N17.6NSleep onset latencyContinuous28 daysA76*Hart*1997NN9373Y21.5NFrequency of improved pain score (VAS)DichotomousDuration of 5 daysA78*Hitzenberger*2005NY??-?NBlood pressureContinuous6 weeksA79^b^Hofmeyr1990YN162161Y0.6NDaily questionnaire responses: those without moderate/severe perineal painDichotomous4 daysA80*Jacobs*2006NN292265Y9.2YDuration of diarrhoeaContinuousUp to 7 daysA81Jacobs2007YN6058N1.7NNo. of days until no pain or fever for at least two consecutive daysContinuousUp to 1 weeksA83^b^Kaziro1984NN7777Y0.0NPain score (VAS): Numbers without moderate/severe pain (imputed)Dichotomous8 daysA84Khuda-Bukhsh2005YN5555N0.0NUrine arsenic concentration (imputed)Continuous11 daysA85Khuda-Bukhsh2011YN2814N50.0NUrine arsenic concentrationContinuous2 monthsA86Kim2005YY4034N15.0YRhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ total symptoms)Continuous4 weeksA88*Kolia-Adam*2008NN3030N0.0NHours of sleep per nightContinuous8 weeksA89Kotlus2010NN6057N5.0NArea of ecchymosisContinuous7 daysA91*Labrecque*1992NY174162Y6.9NProportion of pts with healed warts (physician assessment)Dichotomous18 weeksA92^b^Leaman1989NN3434N0.0NPain (0-10 VAS) - area-under-the-curveContinuous6 hA93Lewith2002NN242202Y16.5YAsthma VAS (imputed)Continuous16 weeksA94Lipman1999NN10190Y10.9NAverage snoring score computed from responses to Snore Diary over last 5 nights of 10ContinuousDuration of 10 daysA293Malapane2014YN3030N0.0NTonsillitis pain score (Wong-Baker FACES)Continuous6 daysA95*McCutcheon*1996NN7758N24.7NState Anxiety scoreContinuousDuration of 15 daysA275Naidoo2013YN3030N0.0NWheal diameterContinuous4 weeksA100Oberbaum2001NN3230N6.3YArea-under-the-curve score for stomatitis symptoms (severity and duration) (imputed)Continuous14 days minimumA101^b^Oberbaum2005YN4540N11.1YVenous haemoglobinContinuous72 h postpartumA103Padilha2011NN131120Y8.4YProportion of workers with Pb decrease of at least 25% (imputed)Dichotomous30 daysA104^b^Papp1998NN372334Y10.2NProportion of patients with physician-assessed recovery in health (i.e. 'no symptoms')DichotomousBy 48 hA105Paris2008NY131105Y19.8YProportion patients with cumulated consumption of morphine \< 10 mg/day (imputed)Dichotomous24 h post-opA108^b^Rahlfs1976YY?63Y?NImprovement of irritable bowel syndrome (scale 1 + 2)Dichotomous14 daysA109^b^Rahlfs1978YN11985Y28.6NImprovement of irritable bowel syndrome (scale 3 + 4)Dichotomous15 daysA277*Razlog*2012YN2018N10.0NConner's PSQ ('Impulsivity and/or hyperactivity' category)Continuous3 weeksA111^b^Reilly1986NY158109Y31.6NPropn. with improvement in daily overall VAS score (imputed)Dichotomous5 weeksA112^b^Reilly1994NY2824N14.3YPropn. with improvement in daily overall VAS scoreDichotomous4 weeksA113Robertson2007NY190111Y41.6NTonsillectomy pain (VAS) scoreContinuous14 daysA116*Schmidt*2002NY208194Y6.7YReduction of body weightContinuous3 daysA117*Seeley*2006NN2926N10.3NArea of ecchymosisContinuous10 daysA278*Sencer*2012NY195106Y45.6NSum of Walsh scores for mucositisContinuousUp to 20 days post-transplantA120Singer2010NY8079Y1.3YArea-under-the-curve pain scoreContinuous14 daysA122*Stevinson*2003YN6462N3.1YPain (Short Form McGill Pain QuestionnaireContinuous14 daysA123^b^Taylor2000NY5150N2.0YDaily overall VAS score (imputed)Continuous3--4 weeksA125Tveiten1991NN4436N18.2NMuscle soreness (VAS) (imputed)Continuous3 daysA126^b^Tveiten1998NN?46N?NMuscle soreness (VAS)Continuous3 daysA128^b^Vickers1998NY?400Y?YMuscle soreness (VAS)Continuous2 daysA130*Weiser*1994NY173155Y10.4NSinusitis scoreContinuous5 months or on relapseA131^b^Wiesenauer1985NN10674Y30.2NSymptom relief (nasal): 'Symptom-free' + 'Obvious relief'Dichotomous4 weeksA132*Wiesenauer*1989NN221152Y31.2NSinusitis scoreContinuous3--4 weeksA133^b^Wiesenauer1990NN243171Y29.6NSymptom relief (nasal): 'Symptom-free' + 'Obvious relief'DichotomousApprox 5 weeksA134Wiesenauer1991NN176106Y39.8NTreatment successDichotomous12 weeksA135^b^Wiesenauer1995NN132120Y9.1NSymptom relief (nasal): 'Symptom-free' + 'Obvious relief'Dichotomous4 weeksA136Wolf2003YN6059N1.7NHaematoma areaContinuous2 weeksA137Zabolotnyi2007NY113113Y5.3YSinusitis severity score cf. Day 0 (imputed)Continuous7 days*ITT* intention to treat, *PP* per protocol, *Y* yes, *N* no^a^Sample size refers to number of legs, not the number of subjects, in the trial^b^Included in meta-analysis by Shang et al. \[<http://www.ispm.unibe.ch/unibe/portal/fak_medizin/ber_vkhum/inst_smp/content/e93945/e93964/e180045/e180897/1433.Study_characteristics_of_homoeopathy_studies_corrected_eng.pdf> (accessed 1 July 2016)\]

Risk of bias and reliable evidence {#Sec19}
----------------------------------

Table [3](#Tab3){ref-type="table"} provides the risk-of-bias details for each of the 75 trials, and sub-divided by: (a) the 54 that could be included in meta-analysis; (b) the 21 that could not be included in meta-analysis. Domains IV (completeness of outcome data), V (selective outcome reporting) and VI (other sources of bias) presented the greatest methodological concerns. Sixteen of 30 trials that were *high risk of bias* for domain V were so because their data were not extractable for meta-analysis (see *Study selection for meta-analysis* above). Domain II (allocation concealment) presented the most uncertain methodological judgments, with 55 (73%) trials assessed *unclear risk of bias* and only 14 (19%) *low risk of bias*.Table 3Risk-of-bias assessments for trials: (a) included in meta-analysis; (b) not included in meta-analysisRisk-of-bias domain\#First authorYearIIIIIIaIIIbIVV ^c^VIRisk of biasRisk-of-bias rating*(a) Included in meta-analysis*A272Colau2012YYYYYYYLow ^a^AA103Padilha2011YYYYYYYLow ^a^AA120Singer2010YYYYYYUUncertain ^a^B1\*A123Taylor2000YUYYYYYUncertainB1A47Baker2003YYYYUYUUncertainB2A61Cornu2010YYUUYYYUncertainB2A67Frass2005UUYYYYYUncertainB2A93Lewith2002UUYYYYYUncertainB2A275Naidoo2013UUYYYYYUncertainB2A105Paris2008UYYYUYYUncertainB2A126Tveiten1998YUYYUYYUncertainB2A128Vickers1998YYYYUYUUncertainB2A137Zabolotnyi2007YUYYYUYUncertainB2A100Oberbaum2001UUYYYYUUncertainB3A62Diefenbach1997UUYUUYYUncertainB4A64Ferley1989UUYUYUYUncertainB4A79Hofmeyr1990YUUUYUYUncertainB4A92Leaman1989UUYYUYUUncertainB4A293Malapane2014UUUUYYYUncertainB4A125Tveiten1991UUYUUYYUncertainB4A135Wiesenauer1995UUYYUYUUncertainB4A112Reilly1994UUUUYYUUncertainB5A48Balzarini2000UUUUUYUUncertainB6A75GRECHO1989UUUUUYUUncertainB6A83Kaziro1984UUUUUYUUncertainB6A104Papp1998UUYUUUUUncertainB6A81Jacobs2007YYYYYYNHighC1.0A131Wiesenauer1985YUYYNYYHighC1.1A68Freitas1995YUYYNYUHighC1.2A111Reilly1986UUYYNYYHighC1.2A113Robertson2007YUYYNYUHighC1.2A133Wiesenauer1990UUYYNYYHighC1.2A86Kim2005YUUUNYYHighC1.3A134Wiesenauer1991UUYUNYYHighC1.3A59Cialdella2001UUUUNYYHighC1.4A63Ernst1990UUUUYYNHighC1.4A56Bignamini1987UUUUUYNHighC1.5A84Khuda-Bukhsh2005UUUUUUNHighC1.6A94Lipman1999UYYYNNYHighC2.1A108Rahlfs1976NNYYUYYHighC2.1A70Friese1997UUYYNNYHighC2.2A74Gerhard (a)1998YUYUNYNHighC2.2A74Gerhard (b)1998YUYUNYNHighC2.2A74Gerhard (c)1998YUYUNYNHighC2.2A89Kotlus2010NNUUYYYHighC2.2A50Belon2006NNUUYYUHighC2.3A136Wolf2003YUUUYNNHighC2.3A49Beer1999UUUUYNNHighC2.4A52Bergmann (a)2000UUYUUNNHighC2.4A52Bergmann (b)2000UUYUUNNHighC2.4A101Oberbaum2005UUUUUNNHighC2.5A60Clark2000UUUUNNNHighC3.4A85Khuda-Bukhsh2011NNYYNNNHighC5.0A109Rahlfs1978NNN ^d^NNYYHighC5.0*(b) Not included in meta-analysis*A80Jacobs2006YYYYYN ^b^YHigh ^f^C1.0A91Labrecque1992YUYYUN ^b^YHigh ^e^C1.2A274Harrison2013YUYYUN ^b^UHigh ^e^C1.3A78Hitzenberger2005UUYUUN ^b^YHigh ^e^C1.4A277Razlog2012UUYYUN ^b^UHigh ^e^C1.4A117Seeley2006UUUUYN ^b^UHigh ^e^C1.5A55Berrebi2001UUUUUN ^b^UHigh ^e^C1.6A76Hart1997YYYYUNYHighC1.1A116Schmidt2002YYYYYN ^b^NHighC2.0A122Stevinson2003YYYYYN ^b^NHighC2.0A278Sencer2012UYYYNN ^b^YHighC2.1A130Weiser1994YUYYNNYHighC2.1A43Aabel2000UUYYYN ^b^NHighC2.2A44Aabel2000UUYYNN ^b^UHighC2.2A42Aabel2001UUUYYN ^b^NHighC2.3A132Wiesenauer1989UUYUNNYHighC2.3A53Bernstein2006UUUUUN ^b^NHighC2.5A69Friese2007UUUUNNNHighC3.4A88Kolia-Adam2008NUUUUNNHighC3.4A95McCutcheon1996UUUUNN ^b^NHighC3.4A51Belon2007NNN ^d^NNN ^b^UHighC6.1Trials are arranged by risk of bias per category (a) and (b)*Y* yes (low risk of bias), *U* unclear, *N* no (high risk of bias)^a^Reliable evidence^b^Data not extractable for meta-analysis^c^Unless a published study protocol was available, completeness of reporting was judged solely on correspondence of Results with details in Methods section of paper^d^A51 Belon and A109 Rahlfs, on initial full-text scanning, were deemed to have satisfactory participant/practitioner blinding -- later refuted in detailed scrutiny^e^Except for domain V (data not extractable for meta-analysis), trial is otherwise *uncertain risk of bias* overall^f^Except for domain V (data not extractable for meta-analysis), trial is otherwise *low risk of bias* overall

There were three trials with *reliable evidence* (two 'A'-rated, one 'B1\*'-rated), 23 with *uncertain risk of bias* ('B'-rated), and 49 with *high risk of bias* ('C'-rated). A summary risk-of-bias bar-graph is shown in Additional file [3](#MOESM3){ref-type="media"}.

Table [3a](#Tab3){ref-type="table"} *(54 trials included in meta-analysis):* Two trials were 'A'-rated (low risk of bias)---i.e. they fulfilled the criteria for all seven domains of assessment. Our criteria for reliable evidence were also satisfied for one 'B1\*'-rated trial. Table [3a](#Tab3){ref-type="table"} therefore includes three trials that were classed *reliable evidence*: *Plumbum metallicum* for lead poisoning (A103: Padilha); the OTC complex *Acthéane* for menopausal syndrome (A272: Colau); the OTC complex *Traumeel S* for post-operative pain (A120: Singer). Each of the other 51 trials had uncertain or high risk of bias in important methodological aspects, and may be regarded as *non-reliable evidence:* 23 trials were classed as *uncertain risk of bias*; 28 were classed as *high risk of bias*.

Table [3b](#Tab3){ref-type="table"} *(21 trials excluded from meta-analysis):* All of these 21 trials are 'C'-rated (high risk of bias). Thirteen of the 21 were seriously flawed in more than one domain of assessment (i.e. rated 'C2.0' or worse). Seven of the remaining eight trials were 'C'-rated solely because of data extraction issues: only one of those seven (A80: Jacobs) fulfilled 'low risk-of-bias' criteria for all other domains of assessment, and so would otherwise have been designated *reliable evidence*.

Meta-analysis {#Sec20}
-------------

The pooled SMD (random-effects model) for all 54 trials was --0.33 (95% CI --0.44, --0.21; *p* \< 0.001)---see Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Forest plot for 54 analysable RCTs of non-individualised homeopathy. Shows SMD (Treatment Effect, TE) and 95% confidence interval (CI). Pooled effects estimate shown for fixed-effect and random-effects model. *W* weighting

The original data extracted per trial (continuous or dichotomous), together with the correspondingly calculated SMD or OR, are illustrated in Additional files [4](#MOESM4){ref-type="media"}a and b.

Of the 31 trials with *continuous data*, 9 had an effect statistically significantly favouring homeopathy (i.e. SMD \< 0, with *p* ≤ 0.05); no trials had an effect significantly favouring placebo. The pooled effect estimate was SMD = --0.36 (95% CI --0.52, --0.19; *p* \< 0.001). Of the 23 trials with *dichotomous data*, 6 had an effect statistically significantly favouring homeopathy (i.e. OR \> 1, with *p* ≤ 0.05); no trials had an effect significantly favouring placebo. The pooled effect estimate was OR = 1.67 (95% CI 1.25, 2.23; *p* \< 0.001).

### Heterogeneity and publication bias {#Sec21}

The statistical heterogeneity among the studies was high (*I* ^2^ = 65%) -- Fig. [2](#Fig2){ref-type="fig"}.

Evidence of publication bias, toward studies favouring homeopathy, was apparent from the funnel plot (Fig. [3a](#Fig3){ref-type="fig"}), which suggested a relative absence of studies favouring placebo. Egger's test of asymmetry confirmed significant evidence of asymmetry in the funnel plot, *p* = 0.002. The estimated number of 'missing' studies was 11 (*p* for at least one 'missing' study was \<0.001) -- Fig. [3b](#Fig3){ref-type="fig"}. The effect estimate was attenuated when using the 'trim-and-fill' method to adjust for publication bias: after adjustment for 'missing' studies, the pooled effect estimate was --0.16 (95% CI --0.31, --0.02; *p* = 0.023); the statistical heterogeneity among the studies remained high (*I* ^2^ = 79%).Fig. 3**a** Funnel plot for 54 RCTs of non-individualised homeopathy. Central *vertical line* is pooled effect estimate: SMD = --0.33. Heterogeneity statistic (*I* ^2^) = 65%. **b** Funnel plot for 54 RCTs of non-individualised homeopathy after 'trim and fill'. Central vertical line is pooled effect estimate: SMD = --0.16. Heterogeneity statistic (*I* ^2^ ) = 79%

### Risk of bias and reliable evidence {#Sec22}

Figure [4](#Fig4){ref-type="fig"} shows the SMD data for all 54 analysable trials, grouped by their risk of bias (high; uncertain; minimal or low \[reliable evidence\]).Fig. 4Forest plots showing SMD (Treatment Effect, TE) and 95% confidence interval (CI) for RCTs of non-individualised homeopathy, with pooled SMD (random-effects model) for trials assessed as *minimal or low risk of bias* (*reliable evidence*; *N* = 3); *uncertain risk of bias* (*non-reliable evidence*; *N* = 23); *high risk of bias* (*non-reliable evidence*; *N* = 28) *High risk of bias/non-reliable evidence* ('C'-rated: *N* = 28): SMD = --0.38 (95% CI --0.50, --0.26; *p* \< 0.001);*Uncertain risk of bias/non-reliable evidence* ('B'-rated: *N* = 23): SMD = --0.31 (95% CI --0.51, --0.11; *p* = 0.002);*Minimal or low risk of bias/reliable evidence* ('B1\*' plus 'A'-rated: *N* = 3): SMD = --0.18 (95% CI --0.46, 0.09; *p* = 0.165).

From this risk-of-bias analysis, no significant difference was detected between the three pooled effect estimates (*p* = 0.417); meta-regression confirmed this finding (*p* = 0.617). There was thus no statistical evidence that effect estimates significantly differed depending on whether the body of evidence for a meta-analysis consisted of 'low', 'uncertain' or 'high' risk-of-bias studies.

Sensitivity analysis {#Sec23}
--------------------

Figure [5](#Fig5){ref-type="fig"} shows the effect of cumulatively removing data by trials' risk-of-bias rating. The pooled SMD showed a statistically significant effect in favour of homeopathy for all trials collectively, through to and including those rated 'B3'; for the highest-rated trials collectively ('B2', 'B1' and 'reliable evidence'), the pooled SMD still favoured homeopathy but was no longer statistically significant.Fig. 5Sensitivity analysis, showing progressive effect on pooled SMD (*treatment effect* TE) of removing data by trials' risk-of-bias rating

Sub-group analyses {#Sec24}
------------------

The pooled SMD favoured homeopathy for all sub-groups, though it was statistically non-significant for two of the 18 (data imputed; combination medicine): Fig. [6a](#Fig6){ref-type="fig"}. A meta-regression was performed to test specifically for within-group differences for each sub-group. The results showed that there were no significant differences between studies that were and were not: included in previous meta-analyses (*p* = 0.447); pilot studies (*p* = 0.316); greater than the median sample (*p* = 0.298); potency ≥ 12C (*p* = 0.221); imputed for meta-analysis (*p* = 0.384); free from vested interest (*p* = 0.391); acute/chronic (*p* = 0.796); different types of homeopathy (*p* = 0.217).Fig. 6Interactions between sub-groups for: **a** all *N* = 54 trials with analysable data; **b** *N* = 26 'A'- and 'B'-rated trials

After removal of 'C'-rated trials (Fig. [6b](#Fig6){ref-type="fig"}), the pooled SMD still favoured homeopathy for all sub-groups, but was statistically non-significant for 10 of the 18 (included in previous meta-analysis; pilot study; sample size \> median; potency ≥12C; data imputed; free of vested interest; not free of vested interest; combination medicine; single medicine; chronic condition). There remained no significant differences *between sub-groups*---with the exception of the analysis for sample size \> median (*p* = 0.028).

### Analysis by clinical condition {#Sec25}

#### Clinical conditions {#FPar1}

Meta-analysis was possible for eight clinical conditions, each analysis comprising two to five trials (Fig. [7a](#Fig7){ref-type="fig"}). A statistically significant pooled SMD, favouring homeopathy, was observed for influenza (*N* = 2), irritable bowel syndrome (*N* = 2), and seasonal allergic rhinitis (*N* = 5). Each of the other five clinical conditions (allergic asthma, arsenic toxicity, infertility due to amenorrhoea, muscle soreness, post-operative pain) showed non-significant findings. Removal of 'C'-rated trials negated the statistically significant effect for seasonal allergic rhinitis and left the non-significant effect for post-operative pain unchanged (Fig. [7b](#Fig7){ref-type="fig"}); no higher-rated trials were available for additional analysis of arsenic toxicity, infertility due to amenorrhoea or irritable bowel syndrome. There were no 'C'-rated trials to remove for allergic asthma, influenza, or muscle soreness. Thus, influenza was the only clinical condition for which higher-rated trials indicated a statistically significant effect; neither of its contributing trials, however, comprised reliable evidence.Fig. 7Meta-analysis by clinical condition for: **a** all *N* = 54 trials with analysable data; **b** *N* = 26 'A'- and 'B'-rated trials. *p* values for pooled effect estimates: **a** Allergic asthma: *p* = 0.307; arsenic toxicity: *p* = 0.219; female infertility (amenorrhoea): *p* = 0.407; influenza: *p* = 0.025; irritable bowel syndrome: *p* = 0.009; muscle soreness: *p* = 0.762; post-operative pain: *p* = 0.143; seasonal allergic rhinitis: *p* = 0.001. **b** Allergic asthma: *p* = 0.307; influenza: *p* = 0.025; muscle soreness: *p* = 0.762; post-operative pain: *p* = 0.859; seasonal allergic rhinitis: *p* = 0.147

### Categories of clinical condition {#Sec26}

Meta-analysis was possible for 11 categories of clinical condition, each analysis comprising two to ten trials (Fig. [8a](#Fig8){ref-type="fig"}). A statistically significant pooled SMD, favouring homeopathy, was observed for five categories: allergy and asthma (*N =* 10); cardiovascular (*N =* 2); dermatology (*N =* 2); ear nose and throat (*N =* 3); gastroenterology (*N =* 2). None of the trials designated reliable evidence featured in any of these five categories. Each of the other six categories showed non-significant findings. Removal of 'C'-rated trials limited each analysis to two to five trials (Fig. [8b](#Fig8){ref-type="fig"}): statistically significant effects were marginally retained for allergy and asthma (*N =* 5) and dermatology (*N =* 2), and more clearly retained for ear nose and throat (*N =* 2). No higher-rated trials were available for additional analysis in the cardiovascular and gastroenterology categories. After removal of 'C'-rated trials, there was no change in the non-significance of the statistical findings for each of the other six categories.Fig. 8Meta-analysis by category of clinical condition for: **a** all *N* = 54 trials with analysable data; **b** *N* = 26 'A'- and 'B'-rated trials. *p* values for pooled effect estimates: **a** Allergy and asthma: *p* = 0.001; Cardiovascular: *p* = 0.046; Dermatology: *p* = 0.047; Ear, nose and throat: *p* = 0.014; Gastroenterology: *p* = 0.009; Mental disorder: *p* = 0.865; Musculoskeletal: *p* = 0.488; Obstetrics and gynaecology: *p* = 0.088; Respiratory infection: *p* = 0.092; Surgery and anaesthesiology: *p* = 0.448; Toxicology: *p* = 0.406. **b** Allergy and asthma: *p* = 0.041; Dermatology: *p* = 0.047; Ear, nose and throat: *p* \< 0.001; Mental disorder: *p* = 0.165; Musculoskeletal: *p* = 0.762; Obstetrics and gynaecology: *p* = 0.486; Respiratory infection: *p* = 0.092; Surgery and anaesthesiology: *p* = 0.576; Toxicology: *p* = 0.896

Discussion {#Sec27}
==========

Seventy-two of the 75 eligible trials had uncertain or high risk of bias. Due to poor reporting or other deficiencies in 21 of the original papers, data extraction for our meta-analysis was possible from only 54 of the 75 trials. Trials with high and with uncertain risk of bias each featured similarly in our 54-trial analysis; the quality of the body of analysed evidence is therefore low.

As previously recognised \[[@CR2], [@CR7], [@CR9]\], the pooling of data from diverse clinical conditions, outcome measures and end-points has obvious limitations: thus, a given pooled effect estimate here does not have a clear numerical meaning or relative clinical value, but provides a reasonable summary measure in evaluating the average effect of a medical intervention. Our null hypothesis that regards each trial of non-individualised homeopathy as testing *the same* intervention also has its limitations, for it makes the debatable assumption that each homeopathic medicine has similar lack of efficacy for the relevant symptoms of every clinical condition. Nevertheless, our separate focus on individualised \[[@CR2]\] and non-individualised homeopathy marks a clear and appropriate step forward.

For our previous meta-analysis of RCTs (on *individualised* homeopathy \[[@CR2]\]), the three most highly ranked trials had minimal risk of bias and were designated reliable evidence. In the current study, we have identified two trials with the highest-quality ranking ('A' = low risk of bias), plus one with minimal risk of bias ('B1\*'), which we have examined collectively as the reliable evidence of RCTs of non-individualised homeopathic treatment. Analysis of these three highest-quality trials showed a statistically non-significant pooled SMD of --0.18 (95% CI --0.46, 0.09) (equivalent to pooled OR = 1.39, using the standard conversion \[[@CR14]\]). This effect estimate of --0.18 contrasts with that for all 54 analysable trials of --0.33 (equivalent to OR = 1.82): the latter represents a small and statistically significant treatment effect favouring homeopathy, akin to our pooled findings for the individualised trials \[[@CR2]\]. We therefore reject the null hypothesis (non-individualised homeopathy is indistinguishable from placebo) on the basis of pooling all studies, but fail to reject the null hypothesis on the basis of the reliable evidence only. Our risk-of-bias analysis and the meta-regression, however, indicate that effect estimates do not significantly differ depending on whether the meta-analysis consists of 'low', 'uncertain' or 'high' risk-of-bias studies.

Lack of clear conclusion above might simply be due to there being too few high-quality trials. With only three studies that can be classified as reliable evidence, it is difficult to separate an effect of homeopathy from the effect of poor quality. The three studies comprising 'reliable' RCT evidence are clinically heterogeneous: *Plumbum metallicum* for lead poisoning (\[[@CR23]\]; null effect); *Acthéane* for menopausal syndrome (\[[@CR24]\]; significant treatment effect; evidence of vested interest); *Traumeel S* for post-operative pain (\[[@CR25]\]; null effect). Since the completion of our defined literature search, we are aware of recently published and potentially eligible RCT papers, whose findings we have yet to explore \[[@CR26]--[@CR29]\]. The limit of detecting an effect of non-individualised homeopathy across all trials may be related to a medicine's degree of dilution, since trials using potency ≥12C failed to show a statistically significant pooled effect that favoured homeopathy (see Fig. [6b](#Fig6){ref-type="fig"}).

In attempting to formulate a reasonable overarching conclusion, it is important also to highlight other findings from our quality-based analyses. For example, the sensitivity analysis that consecutively excluded the lowest-quality trials showed that studies with lower quality tended to report greater benefits of non-individualised homeopathic intervention than studies with higher quality. That RCTs with a higher risk of bias showed a greater benefit for the homeopathy group supports some previous---though not our own \[[@CR2]\]---meta-analysis findings \[[@CR4], [@CR7], [@CR10]\]. Our funnel plot finding of larger effect estimates (in favour of homeopathy) in trials with lower sample size is consistent with observations from RCTs in medicine more widely \[[@CR30]\]. A further perspective, based on our trim-and-fill analysis, is that the true pooled effect estimate is likely to be smaller than initially appreciated: we found evidence of publication bias, with an estimated 11 'missing' studies whose results would favour placebo, adjustment for which yielded an attenuated but still-significant pooled effect estimate of --0.16 for the 54 analysable trials. We are also aware that our analysis reflects per-protocol---not the potentially more robust (but less available) ITT---outcome data, which might have slightly magnified our pooled effect estimate; however, we have addressed the possible impact of incomplete data in rigorous risk-of-bias assessments, as recommended by Cochrane \[[@CR31]\]. The sum of these comments supports a generalised conclusion that a non-individualised homeopathic medicine is indistinguishable from a placebo, but the quality of the evidence is low.

A small and erratic treatment effect in this context may be consistent with the notion that a pre-selected homeopathic medicine, aiming to treat the typical symptoms of a clinical condition, and given to *all* of the relevant trial participants, may match sub-optimally the 'total symptom picture' for an important number of them, leading potentially to diminished efficacy. The quality of the clinical intervention and the suitability of the main outcome measure are the key facets of a trial's *model validity*, i.e. the extent to which a study reflects best clinical practice in that intervention \[[@CR32]\]. Thus, to complete the quality evaluation of homeopathy trials, it is important to accommodate also the assessment of their model validity, emphasising in this case the three trials comprising reliable evidence in non-individualised homeopathic treatment.

We report separately our model validity assessments of these trials, evaluating consequently their overall quality based on a *GRADE*-like principle of 'downgrading' \[[@CR14]\]: two trials \[[@CR23], [@CR25]\] rated here as reliable evidence were downgraded to 'low quality' overall due to the inadequacy of their model validity; the remaining trial with reliable evidence \[[@CR24]\] was judged to have adequate model validity. The latter study \[[@CR24]\] thus comprises the sole RCT that can be designated 'high quality' overall by our approach[5](#Fn5){ref-type="fn"}, a stark finding that reveals further important aspects of the preponderantly low quality of the current body of evidence in non-individualised homeopathy.

Analysis by clinical condition, and following removal of 'C'-rated studies, showed a statistically significant treatment effect in RCTs of non-individualised homeopathy for influenza, and in the categories allergy and asthma, dermatology, and ear nose and throat. None of these analyses included any reliable evidence, however. While these clinical categories do not provide compelling evidence for non-individualised homeopathic treatment, they may contain the most promising targets for future research.

Conclusions {#Sec28}
===========

There was a small, statistically significant, effect of non-individualised homeopathic treatment. However, the finding was not robust to sensitivity analysis based solely on the three trials that comprised reliable evidence: the effect size estimate collectively for those three trials was not statistically significant. There was significant evidence of publication bias in favour of homeopathy. Our meta-analysis of the current reliable evidence base therefore fails to reject the null hypothesis that the outcome of treatment using a non-individualised homeopathic medicine is not distinguishable from that using placebo. Nevertheless, the risk-of-bias analysis and the meta-regression, together with the large preponderance of low-quality evidence, challenge the inference that effect size estimates differ significantly depending on risk-of-bias rating. The assessment of a trial's model validity should also be taken into account in an evaluation of overall study quality in homeopathy. Reliable evidence is lacking for all clinical conditions whose data have enabled separate meta-analysis. Higher-quality RCT research on specified homeopathic medicines is required to enable more decisive interpretation regarding efficacy for given clinical symptoms or conditions. Future trialists need to minimise their studies' risk of bias in all domains, and to improve the clarity of their reporting. Such research might wisely focus on trial design in which only patients that match the relevant 'symptom picture' or match the indications of the selected homeopathic product are those eligible to participate: large trials are therefore indicated.
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Additional file 1:Checklist. *PRISMA* 2009 Checklist. (DOC 66 kb) Additional file 2:Details of records of non-individualised homeopathy included in, and excluded from, systematic review and meta-analysis. SD, standard deviation. In comparison to the protocol \[[@CR3]\], A110 Ramelet has been excluded from this systematic review due to its updated identification as a *prophylaxis* trial. (DOCX 76 kb) Additional file: 3Risk-of-bias bar-graph for 75 RCTs of non-individualised homeopathy. (DOCX 170 kb) Additional file 4:Forest plots, showing (a) standardised mean difference (SMD) and (b) odds ratio (OR), with 95% confidence interval (CI) for original data (continuous or dichotomous) extracted per trial of non-individualised homeopathy. Pooled effects estimate shown for fixed-effect and random-effects model. W, weighting. To ensure consistent direction of measurement with disease severity, sign inversion was applied to the mean value of five trials in (a). \[Reflecting the fact that OR \> 1 favours homeopathy, the direction of change toward homeopathy in plot (b) is to the *right*, thus differing from all other plots\]. (ZIP 15 kb)

CI

:   Confidence interval

*GRADE*

:   Grades of Recommendation, Assessment, Development and Evaluation

ICF

:   International Classification of Functioning

ITT

:   Intention to treat

OR

:   Odds ratio

OTC

:   Over-the-counter

*PRISMA*

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

RCT

:   Randomised controlled trial

SD

:   Standard deviation

SMD

:   Standardised mean difference

WHO

:   World Health Organization

In practice, data were not derivable from the three relevant trials with continuous data: due to the original authors' use of either medians or 'change' data only.

This nomenclature is not intended to be definitive, but a basis for more refined analysis at a later date.

Complete details of all 553 records are available at: <https://www.hri-research.org/hri-research/learning-more-from-existing-evidence/systematic-review-programme/>

Additional file [2](#MOESM2){ref-type="media"} represents an update of the flowchart included in the original study protocol \[[@CR3]\].
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